{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:05:46Z","timestamp":1785855946383,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.09.072","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T06:39:20Z","timestamp":1602139160000},"page":"7458-7463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barr\u00e9 syndrome"],"prefix":"10.1016","volume":"38","author":[{"given":"Elaine R.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.vaccine.2020.09.072_b0005","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2020.09.072_b0010","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems for vaccine adverse events","volume":"85","author":"Rosenthal","year":"1995","journal-title":"Am J Public Health"},{"issue":"11","key":"10.1016\/j.vaccine.2020.09.072_b0015","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/aje\/154.11.1006","article-title":"Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination","volume":"154","author":"Verstraeten","year":"2001","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.09.072_b0020","unstructured":"National Vaccine Childhood Injury Act (NCVIA) \u2013 42 U.S.C. \u00a7 300aa-26 [Accessed April 7, 2020]."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2020.09.072_b0025","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1542\/peds.2010-1722L","article-title":"Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program","volume":"127","author":"Salmon","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.09.072_b0030","unstructured":"CDC Emergency Preparedness for Vaccine Safety. https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/emergencypreparedness\/index.html [accessed 4\/07\/2020]."},{"issue":"3","key":"10.1016\/j.vaccine.2020.09.072_b0035","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"42","key":"10.1016\/j.vaccine.2020.09.072_b0040","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2020.09.072_b0045","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2020.09.072_b0050","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","article-title":"Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990\u20132016","volume":"143","author":"Su","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2020.09.072_b0055","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). Available at: http:\/\/www.meddra.org\/ [accessed 4.07.20]."},{"key":"10.1016\/j.vaccine.2020.09.072_b0060","unstructured":"U.S. Code of Federal Regulations, 21 CFR 600.80. Postmarketing reporting of adverse experiences (2014). Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=600.80 [accessed 4.07.20]."},{"issue":"25","key":"10.1016\/j.vaccine.2020.09.072_b0065","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/j.vaccine.2016.04.021","article-title":"Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990\u20132013","volume":"34","author":"Miller","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2020.09.072_b0070","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1080\/21645515.2018.1456598","article-title":"Post-licensure safety surveillance of zoster vaccine live (Zostavax\u00ae) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006\u20132015","volume":"14","author":"Miller","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"10.1016\/j.vaccine.2020.09.072_b0075","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.vaccine.2018.02.034","article-title":"Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009\u20132015","volume":"36","author":"Arana","year":"2018","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2020.09.072_b0080","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1016\/j.vaccine.2010.09.021","article-title":"Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010","volume":"28","author":"Vellozzi","year":"2010","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2020.09.072_b0085","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/aje\/kws195","article-title":"Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009\u20132010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.vaccine.2020.09.072_b0090","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2020.09.072_b0095","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1016\/j.vaccine.2016.07.019","article-title":"Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009\u20132010 season in the active component U.S. military and civilians aged 17\u201344years reported to the Vaccine Adverse Event Reporting System","volume":"34","author":"Bardenheier","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.072_b0100","unstructured":"Brighton Collaboration Definitions & Guidelines: https:\/\/www.brightoncollaboration.org\/case-definitions (accessed 4\/07\/2020)."},{"issue":"43","key":"10.1016\/j.vaccine.2020.09.072_b0105","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1016\/j.vaccine.2017.09.009","article-title":"Vaccine Safety Datalink Team. Risk of Guillain-Barr\u00e9 Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink","volume":"35","author":"Gee","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2020.09.072_b0110","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/pds.3575","article-title":"Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barr\u00e9 syndrome, encephalitis, or anaphylaxis in the 2012\u20132013 season","volume":"23","author":"Kawai","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.09.072_b0115","unstructured":"ACIP Meeting Archives for June 2013. Vaccine Safety Update. Available at https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/min-archive\/min-jun13.pdf [accessed 05\/01\/2020]."},{"key":"10.1016\/j.vaccine.2020.09.072_b0120","unstructured":"Health.mil, the official website of the Military Health System, available at https:\/\/www.health.mil\/Military-Health-Topics\/Health-Readiness\/Immunization-Healthcare\/Vaccine-Safety-Adverse-Events\/Reporting-Vaccine-Health-Problems\/VAERS-Information [accessed 4\/07\/2020]."},{"issue":"RR-2","key":"10.1016\/j.vaccine.2020.09.072_b0125","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2020.09.072_b0130","unstructured":"Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705\u2013708."},{"issue":"2","key":"10.1016\/j.vaccine.2020.09.072_b0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"36","key":"10.1016\/j.vaccine.2020.09.072_b0140","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1016\/j.vaccine.2015.07.037","article-title":"Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population","volume":"33","author":"Sukumaran","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.072_b0145","unstructured":"Interim Results: State-specific seasonal influenza vaccination coverage \u2013United States, August 2009\u2013January 2010. Morbidity, morbidity and mortality weekly report (MMWR): US department of health and human services centers for disease control and prevention; 2010. p. 477\u201384."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:48:12Z","timestamp":1759402092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20312548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":29,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20312548"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barr\u00e9 syndrome","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}